O'Kennedy, Maretha MCoetzee, PKoekemoer, ODu Plessis, LLourens, CWKwezi, LusisizweDu Preez, IlseMamputha, SiphoRutkowska, Daria ALemmer, Yolandy2022-12-022022-12-022022-08O'Kennedy, M.M., Coetzee, P., Koekemoer, O., Du Plessis, L., Lourens, C., Kwezi, L., Du Preez, I. & Mamputha, S. et al. 2022. Protective immunity of plant-produced African horse sickness virus serotype 5 chimaeric virus-like particles (VLPs) and viral protein 2 (VP2) vaccines in IFNAR-/- mice. <i>Vaccine, 40(35).</i> http://hdl.handle.net/10204/125450264-410X1873-2518https://doi.org/10.1016/j.vaccine.2022.06.079http://hdl.handle.net/10204/12545Next generation vaccines have the capability to contribute to and revolutionise the veterinary vaccine industry. African horse sickness (AHS) is caused by an arbovirus infection and is characterised by respiratory distress and/or cardiovascular failure and is lethal to horses. Mandatory annual vaccination in endemic areas curtails disease occurrence and severity. However, development of a next generation AHSV vaccine, which is both safe and efficacious, has been an objective globally for years. In this study, both AHSV serotype 5 chimaeric virus-like particles (VLPs) and soluble viral protein 2 (VP2) were successfully produced in Nicotiana benthamiana ΔXT/FT plants, partially purified and validated by gel electrophoresis, transmission electron microscopy and liquid chromatography-mass spectrometry (LC-MS/MS) based peptide sequencing before vaccine formulation. IFNAR-/- mice vaccinated with the adjuvanted VLPs or VP2 antigens in a 10 µg prime-boost regime resulted in high titres of antibodies confirmed by both serum neutralising tests (SNTs) and enzyme-linked immunosorbent assays (ELISA). Although previous studies reported high titres of antibodies in horses when vaccinated with plant-produced AHS homogenous VLPs, this is the first study demonstrating the protective efficacy of both AHSV serotype 5 chimaeric VLPs and soluble AHSV-5 VP2 as vaccine candidates. Complementary to this, coating ELISA plates with the soluble VP2 has the potential to underpin serotype-specific serological assays.AbstractenAfrican horse sickness virusAHSVHimaeric virus-like particlesOrbivirusSoluble viral protein 2VLPsVP2ArticleO'Kennedy, M. M., Coetzee, P., Koekemoer, O., Du Plessis, L., Lourens, C., Kwezi, L., ... Lemmer, Y. (2022). Protective immunity of plant-produced African horse sickness virus serotype 5 chimaeric virus-like particles (VLPs) and viral protein 2 (VP2) vaccines in IFNAR-/- mice. <i>Vaccine, 40(35)</i>, http://hdl.handle.net/10204/12545O'Kennedy, Martha M, P Coetzee, O Koekemoer, L Du Plessis, CW Lourens, Lusisizwe Kwezi, Ilse Du Preez, Sipho Mamputha, Daria A Rutkowska, and Yolandy Lemmer "Protective immunity of plant-produced African horse sickness virus serotype 5 chimaeric virus-like particles (VLPs) and viral protein 2 (VP2) vaccines in IFNAR-/- mice." <i>Vaccine, 40(35)</i> (2022) http://hdl.handle.net/10204/12545O'Kennedy MM, Coetzee P, Koekemoer O, Du Plessis L, Lourens C, Kwezi L, et al. Protective immunity of plant-produced African horse sickness virus serotype 5 chimaeric virus-like particles (VLPs) and viral protein 2 (VP2) vaccines in IFNAR-/- mice. Vaccine, 40(35). 2022; http://hdl.handle.net/10204/12545.TY - Article AU - O'Kennedy, Martha M AU - Coetzee, P AU - Koekemoer, O AU - Du Plessis, L AU - Lourens, CW AU - Kwezi, Lusisizwe AU - Du Preez, Ilse AU - Mamputha, Sipho AU - Rutkowska, Daria A AU - Lemmer, Yolandy AB - Next generation vaccines have the capability to contribute to and revolutionise the veterinary vaccine industry. African horse sickness (AHS) is caused by an arbovirus infection and is characterised by respiratory distress and/or cardiovascular failure and is lethal to horses. Mandatory annual vaccination in endemic areas curtails disease occurrence and severity. However, development of a next generation AHSV vaccine, which is both safe and efficacious, has been an objective globally for years. In this study, both AHSV serotype 5 chimaeric virus-like particles (VLPs) and soluble viral protein 2 (VP2) were successfully produced in Nicotiana benthamiana ΔXT/FT plants, partially purified and validated by gel electrophoresis, transmission electron microscopy and liquid chromatography-mass spectrometry (LC-MS/MS) based peptide sequencing before vaccine formulation. IFNAR-/- mice vaccinated with the adjuvanted VLPs or VP2 antigens in a 10 µg prime-boost regime resulted in high titres of antibodies confirmed by both serum neutralising tests (SNTs) and enzyme-linked immunosorbent assays (ELISA). Although previous studies reported high titres of antibodies in horses when vaccinated with plant-produced AHS homogenous VLPs, this is the first study demonstrating the protective efficacy of both AHSV serotype 5 chimaeric VLPs and soluble AHSV-5 VP2 as vaccine candidates. Complementary to this, coating ELISA plates with the soluble VP2 has the potential to underpin serotype-specific serological assays. DA - 2022-08 DB - ResearchSpace DP - CSIR J1 - Vaccine, 40(35) KW - African horse sickness virus KW - AHSV KW - Himaeric virus-like particles KW - Orbivirus KW - Soluble viral protein 2 KW - VLPs KW - VP2 LK - https://researchspace.csir.co.za PY - 2022 SM - 0264-410X SM - 1873-2518 T1 - Protective immunity of plant-produced African horse sickness virus serotype 5 chimaeric virus-like particles (VLPs) and viral protein 2 (VP2) vaccines in IFNAR-/- mice TI - Protective immunity of plant-produced African horse sickness virus serotype 5 chimaeric virus-like particles (VLPs) and viral protein 2 (VP2) vaccines in IFNAR-/- mice UR - http://hdl.handle.net/10204/12545 ER -26000